Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 79 articles:
HTML format
Text format



Single Articles


    October 2017
  1. KIM S, Alsaidan OA, Goodwin O, Li Q, et al
    Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression.
    Cancer Res. 2017 Oct 16. pii: canres.0981.2017.
    PubMed     Text format     Abstract available


  2. PONNUSAMY S, Coss CC, Thiyagarajan T, Watts K, et al
    Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer.
    Cancer Res. 2017 Oct 4. pii: canres.0976.2017.
    PubMed     Text format     Abstract available


  3. DAMASCHKE NA, Yang B, Bhusari S, Avilla M, et al
    Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.
    Cancer Res. 2017;77:5236-5247.
    PubMed     Text format     Abstract available


    September 2017
  4. SAN MARTIN R, Pathak R, Jain A, Jung SY, et al
    Tenascin-C and integrin alpha9 mediate interactions of prostate cancer with the bone microenvironment.
    Cancer Res. 2017 Sep 15. pii: canres.0064.2017.
    PubMed     Text format     Abstract available


  5. LIANG Y, Ahmed M, Guo H, Soares F, et al
    LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
    Cancer Res. 2017 Sep 15. pii: canres.0496.2017.
    PubMed     Text format     Abstract available


    August 2017
  6. WANG L, Song G, Zhang X, Feng T, et al
    PADI2-mediated citrullination promotes prostate cancer progression.
    Cancer Res. 2017 Aug 17. pii: canres.0150.2017.
    PubMed     Text format     Abstract available


  7. JIN L, Garcia J, Chan E, de la Cruz C, et al
    Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer.
    Cancer Res. 2017 Aug 17. pii: canres.0314.2017.
    PubMed     Text format     Abstract available


  8. SCHER HI, Graf RP, Schreiber N, McLaughlin B, et al
    Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.
    Cancer Res. 2017 Aug 17. pii: canres.1353.2017.
    PubMed     Text format     Abstract available


  9. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
    Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer.
    Cancer Res. 2017 Aug 15. pii: canres.0320.2017.
    PubMed     Text format     Abstract available


  10. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
    Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer.
    Cancer Res. 2017 Aug 15. doi: 10.1158/0008-5472.CAN-17-0320.
    PubMed     Text format     Abstract available


  11. BAINOR AJ, Deng FM, Wang Y, Lee P, et al
    Chromatin-associated protein SIN3B prevents prostate cancer progression by inducing senescence.
    Cancer Res. 2017 Aug 14. pii: canres.3410.2016.
    PubMed     Text format     Abstract available


    July 2017
  12. YIN Y, Li R, Xu K, Ding S, et al
    Androgen receptor variants mediate DNA repair after prostate cancer irradiation.
    Cancer Res. 2017 Jul 28. pii: canres.0164.2017.
    PubMed     Text format     Abstract available



  13. Correction: MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.
    Cancer Res. 2017;77:3961.
    PubMed     Text format    


  14. SAHA A, Ahn S, Blando J, Su F, et al
    Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in obese mice.
    Cancer Res. 2017 Jul 7. pii: canres.0284.2017.
    PubMed     Text format     Abstract available


    June 2017
  15. LOVERIDGE CJ, Mui EJ, Patel R, Tan EH, et al
    Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis.
    Cancer Res. 2017;77:3158-3168.
    PubMed     Text format     Abstract available


  16. WANG Y, Wang J, Zhang L, Karatas OF, et al
    RGS12 is a novel tumor suppressor gene in African American prostate cancer that represses AKT and MNX1 expression.
    Cancer Res. 2017 Jun 13. pii: canres.0669.2017.
    PubMed     Text format     Abstract available


    May 2017

  17. Correction: Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells.
    Cancer Res. 2017;77:2772.
    PubMed     Text format    


  18. MALEK R, Gajula RP, Williams RD, Nghiem B, et al
    TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis.
    Cancer Res. 2017 May 8. pii: canres.2797.2016.
    PubMed     Text format     Abstract available


  19. PALTOGLOU S, Das R, Townley SL, Hickey T, et al
    Novel androgen receptor co-regulator GRHL2 exerts both oncogenic and anti-metastatic functions in prostate cancer.
    Cancer Res. 2017 May 4. pii: canres.1616.2016.
    PubMed     Text format     Abstract available


  20. IBRAHIM-HASHIM A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, et al
    Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
    Cancer Res. 2017;77:2242-2254.
    PubMed     Text format     Abstract available


    April 2017
  21. KOLONIN MG, Sergeeva A, Staquicini DI, Smith TL, et al
    Interaction between tumor cell surface receptor RAGE and proteinase 3 mediates prostate cancer metastasis to bone.
    Cancer Res. 2017 Apr 20. pii: canres.0708.2016.
    PubMed     Text format     Abstract available


  22. WEN D, Peng Y, Lin F, Singh RK, et al
    Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer.
    Cancer Res. 2017 Apr 20. pii: canres.2355.2016.
    PubMed     Text format     Abstract available


  23. CHEN HY, Larson PEZ, Bok RA, von Morze C, et al
    Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.
    Cancer Res. 2017 Apr 20. pii: canres.2083.2016.
    PubMed     Text format     Abstract available


    March 2017
  24. KURMIS AA, Yang F, Welch TR, Nickols NG, et al
    A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer.
    Cancer Res. 2017 Mar 30. pii: canres.2503.2016.
    PubMed     Text format     Abstract available


  25. MIAO L, Yang L, Li R, Nava Rodrigues D, et al
    Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer.
    Cancer Res. 2017 Mar 16. pii: canres.2169.2016.
    PubMed     Text format     Abstract available


  26. WEI X, Xu Y, Xu FF, Chaiswing L, et al
    RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells.
    Cancer Res. 2017;77:1345-1356.
    PubMed     Text format     Abstract available


  27. OH DY, Cham J, Zhang L, Fong G, et al
    Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
    Cancer Res. 2017;77:1322-1330.
    PubMed     Text format     Abstract available


    February 2017
  28. THOMAS JD, Longen CG, Oyer HM, Chen N, et al
    Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.
    Cancer Res. 2017 Feb 24. pii: canres.1055.2016.
    PubMed     Text format     Abstract available


  29. ZHANG K, Guo Y, Wang X, Zhao H, et al
    WNT/beta-catenin directs self-renewal symmetric cell division of hTERThigh prostate cancer stem cells.
    Cancer Res. 2017 Feb 16. pii: canres.1887.2016.
    PubMed     Text format     Abstract available


  30. MINCIACCHI VR, Spinelli C, Reis-Sobreiro M, Cavallini L, et al
    MYC mediates large oncosome-induced fibroblast reprogramming in prostate cancer.
    Cancer Res. 2017 Feb 15. pii: canres.2942.2016.
    PubMed     Text format     Abstract available


  31. MANZO T, Sturmheit T, Basso V, Petrozziello E, et al
    T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFalpha Expression and Empower Adoptive Cell Therapy for Solid Tumors.
    Cancer Res. 2017;77:658-671.
    PubMed     Text format     Abstract available


    January 2017
  32. ALFAQIH MA, Nelson ER, Liu W, Safi R, et al
    CYP27A1 loss dysregulates cholesterol homeostasis in prostate cancer.
    Cancer Res. 2017 Jan 27. pii: canres.2738.2016.
    PubMed     Text format     Abstract available


  33. VAN OORSCHOT B, Uitterhoeve L, Oomen I, Ten Cate R, et al
    Prostate cancer patients with late radiation toxicity exhibit reduced expression of genes involved in DNA double strand break repair and homologous recombination.
    Cancer Res. 2017 Jan 20. pii: canres.1966.2016.
    PubMed     Text format     Abstract available


  34. NANDANA S, Tripathi M, Duan P, Chu CY, et al
    Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis.
    Cancer Res. 2017 Jan 20. pii: canres.0497.2016.
    PubMed     Text format     Abstract available


  35. BERNICHTEIN S, Pigat N, Barry Delongchamps N, Boutillon F, et al
    Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.
    Cancer Res. 2017;77:355-365.
    PubMed     Text format     Abstract available


    December 2016
  36. DAS R, Gregory PA, Fernandes RC, Denis I, et al
    MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2.
    Cancer Res. 2016 Dec 23. pii: canres.2529.2016.
    PubMed     Text format     Abstract available


  37. THANGAVEL C, Boopathi E, Liu Y, Haber A, et al
    RB loss promotes prostate cancer metastasis.
    Cancer Res. 2016 Dec 6. pii: canres.1589.2016.
    PubMed     Text format     Abstract available


    November 2016
  38. CHOUDHURY AD, Schinzel AC, Cotter MB, Lis RT, et al
    Castration resistance in prostate cancer is mediated by the kinase NEK6.
    Cancer Res. 2016 Nov 29. pii: canres.0455.2016.
    PubMed     Text format     Abstract available


  39. AUDET-WALSH E, Yee T, McGuirk S, Vernier M, et al
    Androgen-dependent repression of ERRgamma reprograms metabolism in prostate cancer.
    Cancer Res. 2016 Nov 7. pii: canres.1204.2016.
    PubMed     Text format     Abstract available


  40. FONG KW, Zhao JC, Kim J, Li S, et al
    Polycomb-mediated disruption of an androgen receptor feedback loop drives castration-resistant prostate cancer.
    Cancer Res. 2016 Nov 4. pii: canres.1949.2016.
    PubMed     Text format     Abstract available


  41. GELMAN IH
    How the TRAMP Model Revolutionized the Study of Prostate Cancer Progression.
    Cancer Res. 2016;76:6137-6139.
    PubMed     Text format    


    October 2016
  42. DAY KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, et al
    HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone.
    Cancer Res. 2016 Oct 28. pii: canres.1656.2016.
    PubMed     Text format     Abstract available


    September 2016
  43. VARZAVAND A, Hacker W, Ma D, Gibson-Corley KN, et al
    alpha3beta1 Integrin suppresses prostate cancer metastasis via regulation of the Hippo pathway.
    Cancer Res. 2016 Sep 28. pii: canres.1483.2016.
    PubMed     Text format     Abstract available


  44. XIE M, Vesuna F, Tantravedi S, Bol GM, et al
    RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3.
    Cancer Res. 2016 Sep 12. pii: canres.0440.2016.
    PubMed     Text format     Abstract available


    August 2016
  45. ZHANG L, Wang J, Wang Y, Zhang Y, et al
    MNX1 is oncogenically upregulated in African-American prostate cancer.
    Cancer Res. 2016 Aug 30. pii: canres.0087.2016.
    PubMed     Text format     Abstract available


  46. WANG Y, Dehigaspitiya DC, Levine PM, Profit AA, et al
    Multivalent peptoid conjugates suppress enzalutamide-resistant prostate cancer cellular proliferation.
    Cancer Res. 2016 Aug 3. pii: canres.0385.2016.
    PubMed     Text format     Abstract available


  47. TSAI CH, Tzeng SF, Chao TK, Tsai CY, et al
    Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells.
    Cancer Res. 2016 Aug 2. pii: canres.0641.2016.
    PubMed     Text format     Abstract available


    July 2016
  48. LU H, Wang T, Li J, Fedele C, et al
    alphavbeta6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor.
    Cancer Res. 2016 Jul 22. pii: canres.0543.2016.
    PubMed     Text format     Abstract available


    June 2016
  49. STOPSACK KH, Gerke TA, Sinnott JA, Penney KL, et al
    Cholesterol metabolism and prostate cancer lethality.
    Cancer Res. 2016 Jun 20. pii: canres.0903.2016.
    PubMed     Text format     Abstract available


  50. YOU S, Knudsen BS, Erho N, Alshalalfa M, et al
    Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome.
    Cancer Res. 2016 Jun 14. pii: canres.0902.2016.
    PubMed     Text format     Abstract available


    May 2016
  51. SHEIKH NA, Cham J, Zhang L, DeVries T, et al
    Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.
    Cancer Res. 2016 May 23. pii: canres.3173.2015.
    PubMed     Text format     Abstract available


  52. SATO S, Katsushima K, Shinjo K, Hatanaka A, et al
    Histone deacetylase inhibition in prostate cancer triggers miR-320-mediated suppression of the androgen receptor.
    Cancer Res. 2016 May 23. pii: canres.3339.2015.
    PubMed     Text format     Abstract available


  53. ALBINO D, Civenni G, Dallavalle C, Roos M, et al
    Activation of the Lin28/let7 axis by loss of ESE3/EHF promotes a tumorigenic and stem-like phenotype in prostate cancer.
    Cancer Res. 2016 May 2. pii: canres.2665.2015.
    PubMed     Text format     Abstract available


  54. FERRALDESCHI R, Welti J, Powers MV, Yuan W, et al
    Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
    Cancer Res. 2016;76:2731-2742.
    PubMed     Text format     Abstract available


    April 2016
  55. PASERO C, Gravis G, Guerin M, Granjeaud S, et al
    Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
    Cancer Res. 2016;76:2153-65.
    PubMed     Text format     Abstract available


  56. YU X, Wang H, Li X, Guo C, et al
    Activation of the MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity.
    Cancer Res. 2016;76:2166-76.
    PubMed     Text format     Abstract available


  57. LINDQUIST KJ, Paris PL, Hoffmann TJ, Cardin NJ, et al
    Mutational Landscape of Aggressive Prostate Tumors in African American Men.
    Cancer Res. 2016;76:1860-8.
    PubMed     Text format     Abstract available


    March 2016
  58. PEITZSCH C, Cojoc M, Hein L, Kurth I, et al
    An epigenetic reprogramming strategy to re-sensitize radioresistant prostate cancer cells.
    Cancer Res. 2016 Mar 16. pii: canres.2116.2015.
    PubMed     Text format     Abstract available


  59. PRUEITT RL, Wallace TA, Glynn SA, Yi M, et al
    An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers.
    Cancer Res. 2016;76:1055-65.
    PubMed     Text format     Abstract available


  60. BILIR B, Osunkoya AO, Wiles WG 4th, Sannigrahi S, et al
    SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.
    Cancer Res. 2016;76:1112-21.
    PubMed     Text format     Abstract available


  61. ARGYROS O, Karampelas T, Asvos X, Varela A, et al
    Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.
    Cancer Res. 2016;76:1181-92.
    PubMed     Text format     Abstract available


    February 2016
  62. MIFTAKHOVA R, Hedblom A, Semenas J, Robinson BD, et al
    Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow.
    Cancer Res. 2016 Feb 26. pii: canres.2340.2015.
    PubMed     Text format     Abstract available


  63. TRAVIS RC, Appleby PN, Martin RM, Holly JM, et al
    A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk.
    Cancer Res. 2016 Feb 26. pii: canres.1551.2015.
    PubMed     Text format     Abstract available


  64. LINN DE, Penney KL, Bronson RT, Mucci LA, et al
    Deletion of interstitial genes between TMPRSS2 and ERG promotes prostate cancer progression.
    Cancer Res. 2016 Feb 15. pii: canres.1911.2015.
    PubMed     Text format     Abstract available


  65. NAKAJIMA K, Kho DH, Yanagawa T, Harazono Y, et al
    Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis.
    Cancer Res. 2016 Feb 2. pii: canres.1793.2015.
    PubMed     Text format     Abstract available


    January 2016
  66. YAN J, Ojo D, Kapoor A, Lin X, et al
    Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer.
    Cancer Res. 2016 Jan 21. pii: canres.1898.2015.
    PubMed     Text format     Abstract available


  67. NELSON WG
    Commentary on Huggins and Hodges: "Studies on Prostatic Cancer".
    Cancer Res. 2016;76:186-7.
    PubMed     Text format    


  68. LI N, Dhar SS, Chen TY, Kan PY, et al
    JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis.
    Cancer Res. 2016 Jan 8. pii: canres.0906.2015.
    PubMed     Text format     Abstract available


    December 2015
  69. MARTIN SK, Pu H, Penticuff JC, Cao Z, et al
    Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer.
    Cancer Res. 2015 Dec 8. pii: canres.2078.2015.
    PubMed     Text format     Abstract available


    November 2015
  70. CASIMIRO MC, Di Sante G, Ju X, Li Z, et al
    Cyclin D1 promotes androgen-dependent DNA damage repair in prostate cancer cells.
    Cancer Res. 2015 Nov 18. pii: canres.0999.2015.
    PubMed     Text format     Abstract available


  71. SHI XB, Ma A, Xue L, Li M, et al
    miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2 and Src.
    Cancer Res. 2015 Nov 16. pii: canres.0795.2014.
    PubMed     Text format     Abstract available


  72. TA HQ, Ivey ML, Frierson HF Jr, Conaway MR, et al
    Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  73. SPRATT DE, Evans MJ, Davis BJ, Doran MG, et al
    Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.
    Cancer Res. 2015;75:4688-96.
    PubMed     Text format     Abstract available


    October 2015
  74. HURLEY PJ, Hughes RM, Simons BW, Huang J, et al
    Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
    Cancer Res. 2015;75:4322-34.
    PubMed     Text format     Abstract available


  75. WANG M, Kimbrell HZ, Sholl AB, Tulman DB, et al
    High-Resolution Rapid Diagnostic Imaging of Whole Prostate Biopsies Using Video-Rate Fluorescence Structured Illumination Microscopy.
    Cancer Res. 2015;75:4032-41.
    PubMed     Text format     Abstract available


    September 2015
  76. BERNARDO MM, Kaplun A, Dzinic SH, Li X, et al
    Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.
    Cancer Res. 2015;75:3970-9.
    PubMed     Text format     Abstract available


  77. XU D, Zhan Y, Qi Y, Cao B, et al
    Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.
    Cancer Res. 2015;75:3663-71.
    PubMed     Text format     Abstract available


    April 2015
  78. BROWN M, Chinnaiyan A, Farsetti A, Livingston DM, et al
    26th Pezcoller symposium: cancers driven by hormones.
    Cancer Res. 2015;75:1177-80.
    PubMed     Text format     Abstract available


  79. FOX JL, Storey A
    BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.
    Cancer Res. 2015;75:1345-55.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: